Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 2002

View Archived Issues

Remedyne licenses Bayer antigen for use in cancer immunotherapeutic

Biovitrum initiates phase I trials of BVT-3498

NGD-96-3 enters phase I trials

OrthoLogic's IND approved for phase I/II trial of Chrysalin in spinal fusion

Synt:em licenses Pep:trans technology to Corixa for vaccine development

Recent studies support first-line use of tiotropium as maintenance therapy in COPD patients

Synthetic peptide sensitizes leukemia cell lines to hyperthermia

Superiority of enoxaparin over unfractionated heparin sustained over one year

Inhibition of membrane synthesis as a target for the development of new antimalarials

Calcilytic compounds presented as a new therapy for bone and mineral diseases

New compounds for the treatment of CNS disorders reported by Lundbeck

Investigators at Banyu identify a series of selective muscarinic M3 receptor antagonists

Serine protease inhibitors of HCV reported by Schering-Plough and Corvas

New lead cPLA2 inhibitor designed at AstraZeneca

Leukocyte adhesion inhibitors reported useful for a wide range of inflammatory diseases

Update of Miravant's ophthalmology, dermatology and cardiovascular PhotoPoint programs

Promising preclinical results for Celgene's JNK inhibitors

Ad5FGF4 improves myocardial perfusion in phase II trial

Atrix licenses Israeli Eligard marketing rights to Luxembourg

Serono reintroduces Crinone in U.S.

SBIR grant for research into ATL-146e in prevention of injury from spinal cord ischemia

CPMP recommends approval of irbesartan in diabetic renal disease

PowderJect submits MAA for Dukoral cholera and travel diarrhea vaccine

Myriad Genetics and Abbott collaborate to discover drugs for depression

Essential Therapeutics completes acquisition of Maret

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...